Sulfasalazine

Introduction Overview

Generic Name

sulfasalazine

Brand Name

Azulfidine
Azulfidine EN-tabs

Dosage Form

oral tablet
oral delayed-release tablet (enteric-coated)

Drug Class

5-aminosalicylates
Antirheumatics
Disease-modifying anti-rheumatic drugs (DMARDs)

Pharmacokinetics

Absorption:
Sulfasalazine is administered orally and exhibits minimal absorption in the small intestine due to its large molecular structure. The drug is designed to reach the colon largely intact, where local bacterial flora enzymatically cleave the azo bond linking 5-aminosalicylic acid (5-ASA) and sulfapyridine. This cleavage releases 5-ASA, the active moiety exerting local anti-inflammatory effects in the colon, particularly relevant to ulcerative colitis treatment. The sulfapyridine moiety is absorbed systemically and is chiefly responsible for systemic effects, including those relevant to rheumatoid arthritis. Absorption is influenced by gastrointestinal transit time, colonic bacterial populations, and integrity of the intestinal mucosa. The use of enteric-coated delayed-release tablets minimizes premature dissolution in the stomach and reduces gastrointestinal irritation, improving tolerability. Clinical implications include variable systemic exposure of sulfapyridine, which is influenced by acetylation phenotype, liver function, and intestinal flora composition.

Distribution:
Following systemic absorption, sulfapyridine is widely distributed in body tissues and fluids, including synovial fluid, which is clinically pertinent in rheumatoid arthritis. Sulfasalazine and its metabolites exhibit moderate plasma protein binding; sulfapyridine binds primarily to albumin. The 5-ASA component, acting locally in the colon, has limited systemic distribution due to minimal absorption. Sulfapyridine's volume of distribution approximates 0.3 to 0.6 L/kg. The drug crosses the placental barrier and is present in breast milk, which necessitates caution in pregnancy and lactation. The distribution phase is relatively rapid, with sulfapyridine potentially accumulating in tissues with repeated dosing. Distribution characteristics are key to understanding exposure of target tissues and systemic toxicity.

Metabolism:
Sulfasalazine undergoes extensive bacterial azo reduction in the colon to split into two primary metabolites: 5-ASA and sulfapyridine. The colonic bacteria are indispensable for this activation step. Sulfapyridine then undergoes hepatic metabolism, primarily through acetylation by N-acetyltransferase enzymes, hydroxylation, and glucuronidation. The acetylator phenotype (slow vs. fast) significantly affects sulfapyridine plasma levels, pharmacokinetics, and adverse effect profiles. 5-ASA is metabolized locally in the intestinal mucosa and liver primarily by N-acetylation to N-acetyl-5-aminosalicylic acid, which is inactive. Hepatic function impairment or alterations of gut flora can affect metabolite levels. Understanding metabolism is crucial for predicting interindividual variability and potential drug interactions.

Elimination:
Sulfapyridine and its metabolites are predominantly eliminated by renal excretion, with approximately 15-30% eliminated unchanged in urine. The elimination half-life of sulfapyridine ranges around 6 to 17 hours, depending on the acetylator status; slow acetylators have prolonged half-lives leading to higher systemic exposure. 5-ASA and its metabolites are mainly excreted via feces and urine. Enteric-coated formulations result in delayed release and altered elimination kinetics. Impaired renal function may require monitoring due to reduced excretion and potential accumulation. Sulfasalazine is mostly cleared from the body over 1.5 to 2 days, with sulfapyridine metabolites cleared over 2 to 3.5 days, emphasizing the necessity for dose adjustments and careful monitoring in susceptible populations.

Dosage Forms

Available Dosage Forms:
- Oral Tablets: Standard sulfasalazine tablets typically contain 500 mg of sulfasalazine.
- Oral Delayed-Release Tablets (Enteric-Coated): Known as Azulfidine EN-tabs, these tablets are coated with polymers and waxes (including white wax, carnauba wax, cellacefate, polyethylene glycol 20000, and others) to ensure delayed release in the intestines, minimizing gastric irritation.

Dosages for Adults and Adolescents:
- For Ulcerative Colitis (Adults): Initial dose of 3 to 4 grams per day divided into 2 to 4 doses; maintenance dose typically 2 grams daily in divided doses. A lower starting dose of 1 to 2 grams may be used to reduce gastrointestinal side effects.
- For Ulcerative Colitis (Children ≥ 6 years): Initial dose 40 to 60 mg/kg/day divided into 3 to 6 doses; maintenance dose approximately 30 mg/kg/day divided into 4 doses.
- For Rheumatoid Arthritis (Adults): Maintenance dose is 2 grams daily in 2 divided doses. Initial dosing starts lower (0.5 to 1 gram daily) with incremental titration weekly over 4 weeks.
- For Juvenile Rheumatoid Arthritis (Children ≥ 6 years, polyarticular course): Maintenance dose 30 to 50 mg/kg daily in two divided doses, maximum dose typically 2 grams per day; gradual titration over one month to minimize side effects.

Specific Patient Populations:
- In patients with gastrointestinal intolerance, delayed-release, enteric-coated tablets are preferred to mitigate nausea, vomiting, and gastric upset.
- Dosage adjustments may be necessary for patients with renal or hepatic impairment due to altered elimination and metabolism.
- Pediatric usage is limited to children 6 years and above; safety and efficacy in children under 2 years is not established.
- Use during pregnancy requires caution; supplementation with folic acid is advised due to potential interference with folate metabolism.
- Breastfeeding mothers should be cautious due to passage in breast milk and potential neonatal risks.
Note: Sulfasalazine tablets should be taken multiple times daily (ranging from 2 to 6 times), preferably after meals with a full glass of water. Enteric-coated tablets must be swallowed whole and not crushed or chewed.

Mechanism Of Action

Sulfasalazine is a prodrug composed of 5-aminosalicylic acid (5-ASA) linked via an azo bond to sulfapyridine. Its mechanism involves dual action that targets both local and systemic inflammatory processes. Upon oral administration, sulfasalazine passes largely intact to the colon, where commensal bacterial azoreductases cleave the bond releasing 5-ASA and sulfapyridine as active metabolites.

The 5-ASA moiety exerts its therapeutic effect primarily through local anti-inflammatory actions in the colonic mucosa. It inhibits cyclooxygenase and lipoxygenase pathways, reducing the production of pro-inflammatory prostaglandins and leukotrienes. Additionally, 5-ASA scavenges reactive oxygen species, inhibits nuclear factor kappa B (NF-κB) activation, and modulates cytokine production, contributing to decreased mucosal inflammation in ulcerative colitis.

The sulfapyridine component is largely responsible for systemic effects seen in rheumatoid arthritis and other inflammatory conditions. It exhibits immunomodulatory properties by suppressing T-cell proliferation and function and reducing production of inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α). Sulfapyridine also affects neutrophil function and inhibits prostaglandin synthesis, contributing to the reduction of joint inflammation and injury.

While the precise molecular targets of sulfasalazine have not been fully elucidated, cumulative evidence from clinical and in vitro studies supports its role as a disease-modifying anti-rheumatic drug (DMARD). Its slow onset of action corresponds with gradual modulation of immune pathways leading to reduced inflammation and joint damage. Compared to other DMARDs, sulfasalazine has a distinct mechanism involving alteration of gut flora metabolism and resultant local and systemic immunomodulation. Clinical studies demonstrate that this dual action confers benefit in both gastrointestinal and rheumatological inflammatory diseases. Ongoing research continues to characterize its complex interactions at molecular and cellular levels.

Pharmacological Actions

Acts as an anti-inflammatory agent primarily through its 5-aminosalicylic acid (5-ASA) component.
Functions as a disease-modifying anti-rheumatic drug (DMARD) by modulating immune responses.
Inhibits cyclooxygenase and lipoxygenase pathways, decreasing prostaglandin and leukotriene synthesis.
Suppresses pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1).
Modulates T-cell proliferation and function, contributing to reduced autoimmune activity.
Exerts antioxidant effects by scavenging reactive oxygen species in inflamed tissues.
Reduces mucosal inflammation in ulcerative colitis by targeting local immune and inflammatory pathways.
Alters neutrophil function and chemotaxis, diminishing inflammatory cell infiltration.
Demonstrates immunomodulatory properties useful in juvenile rheumatoid arthritis and other inflammatory arthropathies.
Delivers localized therapeutic action in the colon while providing systemic immunosuppression via sulfapyridine metabolite.
Supports remission maintenance in ulcerative colitis by prolonging periods without acute exacerbation.
May reduce joint damage progression by limiting chronic inflammation and synovial degradation.
Its metabolite sulfapyridine exhibits antibacterial activity, contributing marginally to its therapeutic profile.
Slow onset of action in rheumatoid arthritis reflects gradual modification of immune-mediated processes.
Exerts no direct steroidogenic effects, distinguishing it from corticosteroid treatments.

Therapeutic Or Clinical Uses

Treatment of mild to moderate ulcerative colitis, inducing and maintaining remission.
Adjunctive therapy in severe ulcerative colitis to prolong remission intervals.
Management of rheumatoid arthritis in adults inadequately responding to salicylates or NSAIDs.
Treatment of polyarticular-course juvenile rheumatoid arthritis in children aged 6 years and older.
Reduction of inflammation and prevention of joint damage progression in chronic inflammatory arthritis.
Off-label use in ankylosing spondylitis to reduce inflammatory symptoms.
Off-label use in Crohn's disease for mucosal inflammation management.
Treatment of psoriatic arthritis to decrease joint swelling and pain.
Used as a steroid-sparing agent to minimize corticosteroid dosage and adverse effects.
Adjunct to other immunomodulatory therapies to improve disease control in autoimmune conditions.
Employed in complex inflammatory bowel disease cases requiring maintenance therapy.
Used to prolong symptom-free periods and reduce acute flare-ups in inflammatory bowel and joint diseases.
Therapeutic option for patients intolerant to biologic agents or advanced DMARDs.
Utilized for its dual colonic and systemic mechanism in diseases involving mucosal and systemic inflammation.
Treatment initiated with gradual dose titration to enhance tolerability and safety.

Side Or Adverse Effects

Common gastrointestinal disturbances including nausea, vomiting, and gastric upset.
Headache and general malaise reported frequently during therapy initiation.
Temporary reversible reduction in sperm count in males leading to infertility concerns.
Skin reactions such as rash, urticaria, and pruritus (itching).
Fever and flu-like symptoms possibly indicating hypersensitivity.
Alterations in blood cell counts including leukopenia, anemia, and thrombocytopenia.
Cyanosis (bluish discoloration) of hands and feet due to hypoxia in rare cases.
Orange-yellow discoloration of urine and occasionally skin, benign and reversible.
Severe hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS).
Potential hepatotoxicity manifesting as elevated liver enzymes, jaundice, or hepatitis.
Nephrotoxicity with possible kidney damage necessitating monitoring of renal function.
Increased susceptibility to serious infections including sepsis and pneumonia.
Neurological adverse events such as peripheral neuropathy or aseptic meningitis in rare cases.
Rare occurrence of alopecia linked to severe hypersensitivity reactions.
Hypersensitivity pneumonitis and other pulmonary complications are rare but reported.

Precautions

Monitor complete blood counts regularly to detect hematologic toxicity early.
Closely monitor liver and kidney function tests during prolonged treatment.
Use caution in patients with a history of recurrent or chronic infections due to immunosuppression.
Exercise caution in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency to avoid hemolysis.
Evaluate for history of severe allergies or bronchial asthma, which may predispose to hypersensitivity.
Adjust dosing and monitor for gastrointestinal intolerance; consider enteric-coated formulation if needed.
Supplement folic acid during therapy to mitigate risk of folate deficiency and neural tube defects in pregnancy.
Cautious use in pregnancy and breastfeeding; assess risk-benefit and consult healthcare provider.
Advise patients about possible orange-yellow discoloration of urine and skin to reduce concerns.
Monitor male fertility status if therapy is prolonged; advise regarding reversible sperm count reduction.
Avoid abrupt withdrawal to prevent disease flare; adherence to prescribed dosing schedules is essential.
Educate patients on symptoms of severe allergic reactions and infections requiring immediate medical attention.
Use cautiously in patients with intestinal or urinary obstruction.
Periodic ophthalmologic examination recommended due to rare reports of visual disturbances.
Maintain awareness of potential drug interactions that may potentiate adverse effects.

Warnings

Risk of serious and potentially fatal hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, most commonly occurring in the first month of treatment.
Potential for liver, kidney, and hematologic toxicity necessitating regular laboratory monitoring.
Increased susceptibility to serious infections, including fatal sepsis and pneumonia, due to immunosuppressive effects.
Temporary infertility in men with low sperm counts, usually reversible upon drug discontinuation.
Use during pregnancy requires caution due to potential risk of neural tube defects linked to folate metabolism interference.
Passage into breast milk may cause kernicterus and other adverse effects in neonates; caution advised during breastfeeding.
Not recommended in patients with known allergy to sulfonamides, salicylates, or sulfasalazine metabolites.
Patients with porphyria should avoid sulfasalazine due to risk of exacerbation.
Gastrointestinal obstruction is a contraindication given risk of worsening obstruction or inadequate drug release.
Adverse effects such as severe rash, fever, or lymphadenopathy warrant immediate drug discontinuation and medical evaluation.
Risk of photosensitivity and skin reactions require advising patients to minimize sun exposure.
Slow acetylators may experience higher systemic exposure and greater incidence of side effects.
Abrupt discontinuation may precipitate disease flare; a gradual taper is preferred if discontinuing.
Risk of blood dyscrasias requires patients to report signs of infection, bleeding, or bruising promptly.
Delayed onset of therapeutic effect necessitates continued use with symptomatic therapies during initial treatment phase.

Contraindication

Known hypersensitivity to sulfasalazine, sulfonamide antibiotics, salicylates, or any component of the formulation.
History of severe allergic or anaphylactic reactions to sulfasalazine or related compounds.
Presence of intestinal or urinary tract obstruction to prevent exacerbation of blockages.
Patients diagnosed with porphyria as sulfasalazine may precipitate attacks.
Use in infants younger than 2 years is contraindicated due to lack of established safety.
Severe hepatic or renal impairment where drug metabolism and elimination are significantly compromised.
Pregnancy where benefits do not outweigh risks, especially if folate supplementation is not feasible.
Patients with active severe infections may have worsened outcomes due to immunosuppression.
Concomitant use with other drugs causing bone marrow suppression without close monitoring.
Previous occurrence of severe dermatologic reactions such as Stevens-Johnson syndrome with the drug.

Drug Interactions

May reduce absorption and efficacy of folic acid supplements, necessitating folate monitoring and supplementation.
Concomitant use with methotrexate may increase gastrointestinal side effects, particularly nausea.
Potential interaction with digoxin by reducing its absorption, warranting therapeutic drug monitoring.
Possible additive immunosuppressant effects when combined with other DMARDs or biologics, increasing infection risk.
Concurrent use with other sulfonamides may potentiate hypersensitivity and toxicity.
May interfere with the efficacy of antibiotics such as penicillins and tetracyclines through altered gut flora.
The acetylation status and liver function can affect metabolism of concomitant drugs metabolized by similar enzymatic pathways.
Concomitant use with anticoagulants like warfarin may alter anticoagulant effect requiring INR monitoring.
Use with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase gastrointestinal irritation risk.
Potential to affect renal elimination of drugs such as lithium, requiring monitoring of renal function and drug levels.
Interactions with antimalarial agents and potential additive hematologic adverse effects.
May alter cytochrome P450 enzyme activity slightly, affecting metabolism of certain drugs though clinically significant interactions are uncommon.
Concurrent use with corticosteroids requires monitoring due to immunomodulatory overlap.
Use caution with drugs causing bone marrow suppression due to additive hematologic toxicity risk.
Herbal supplements influencing immune function should be used cautiously to avoid unpredictable interactions.

Preparations Of The Drug

Azulfidine tablets – standard oral sulfasalazine tablets containing 500 mg sulfasalazine per tablet, including inactive ingredients such as magnesium stearate, povidone, silicon dioxide, and corn starch.
Azulfidine EN-tabs – enteric-coated, delayed-release tablets designed to dissolve in the intestines to minimize gastrointestinal side effects; contain excipients including white wax, carnauba wax, cellacefate, magnesium stearate, polyethylene glycol 20000, propylene glycol, glyceryl stearate SE, silicon dioxide, corn starch, and talc.
Generic sulfasalazine formulations produced by various manufacturers such as Actavis Pharma, Chartwell RX, and Greenstone LLC, with variable inactive ingredients depending on formulation.
Tablets designed for oral administration with dosing regimens ranging from multiple daily doses, often 2 to 6 times daily.
Enteric-coated tablets should be swallowed whole without crushing or chewing to ensure proper delayed release profile.
Available preparations are intended for chronic administration in inflammatory bowel disease and rheumatologic conditions with tailored dose titration schedules.
Packaging typically involves blister packs or bottles to ensure drug stability at room temperature (~25°C).
Storage recommendations include maintaining room temperature away from moisture and light, protected from children’s reach.
Formulations are available in doses to allow flexibility in titration from low starting doses to therapeutic maintenance levels.
No injectable or intravenous formulations are commercially available; oral route is standard.
Preparations require proper labeling to inform about possibility of urine discoloration and other characteristic side effects.
Prescription-only availability necessitates medical supervision for initiation and dose adjustment.
Product information includes guidance on handling missed doses, overdose management, and contraindications.
Manufacturers provide patient information leaflets detailing administration instructions, side effects, and precautions.
Ongoing quality assurance ensures consistent potency and bioavailability across batches.